Targeted Protein Degraders: Key strategies to Maximize VC Funding and Clinical Success
Summary: In this webinar, experts will explore the current investment and clinical landscape of TPD. They will provide insights on how to best position TPD to attract VC funding, how TPD have distinct advantages over more traditional inhibiting drugs, and the importance of tailored developability assessment in identifying lead TPD candidates with high likelihood of clinical success.